Trial Profile
Phase III trial evaluating the role of adjuvant pegylated liposomal doxorubicin (PLD, Caelyx, Doxil) for women (age 66 years or older) with endocrine nonresponsive breast cancer who are not suitable for being offered a 'standard chemotherapy regimen'
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Methotrexate
- Indications Ductal carcinoma; Early breast cancer; Menopause
- Focus Therapeutic Use
- Acronyms CASA
- 14 Oct 2021 This trial has been completed in France (End Date: 31 Dec 2011), according to European Clinical Trials Database record.
- 20 Jul 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
- 20 Jul 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.